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Purposes: To construct a recombinant vaccine alpha-fetoprotein (AFP)-heat shock protein (HSP70) complex, and 
study its ability to induce specific CTL response and its protective effect against AFP-producing tumor. 
Material/Methods: A recombinant vaccine was constructed by conjugating mouse alpha-fetoprotein to heat shock 
protein 70. By way of intracutaneous injection, mice were primed and boosted with recombinant vaccine 
mAFP/HSP70, whereas single mAFP or HSP70 injection as controls. The ELISPOT and ELISA were used to 
measure the frequency of cells producing the cytokine IFN-  in splenocytes and the level of anti-AFP antibody of 
serum from immunized mice respectively. In vivo tumor challenge were carried out to assess the immune effect of 
the recombinant vaccine. Results: By recombinant mAFP/HSP70 vaccine immunization, the results of ELISPOT and 
ELISA showed that the number of splenic cells producing IFN-  and the level of anti-AFP antibody of serum were 
significantly higher in mAFP/HSP70 group than those in mAFP and HSP70 groups (108.50 11.70 IFN-  spots/106 
cells vs 41.60 10.40 IFN-  spots/106 cells, 7.32 3.14 IFN-  spots/106 cells, P<0.01; 156.32 10.42 μg/mL vs 
66.52 7.35 μg/mL, 5.73 2.89 μg/mL, P<0.01). The tumor volume in mAFP/HSP70 group was significantly 
smaller than that in mAFP and HSP70 groups (42.44 7.14 mm3 vs 392.23 12.46 mm3, 838.63 13.84 mm3, 
P<0.01). Conclusions: The study further confirmed the function of heat shock protein 70’s immune adjuvant. 
Sequential immunization with recombinant mAFP/HSP70 vaccine could generate effective antitumor immunity on 
AFP-producing tumor. The recombined mAFP/HSP70 vaccine may be suitable for serving as an immunotherapy for 
hepatocellular carcinoma. 
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Introduction 
The incidence of hepatocellular carcinoma (HCC) is increasing worldwide and accounts for as many as 
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1.2 million deaths annually. It is also rising rapidly in China because of hepatitis B and C infections [1,2]. 
Although surgery and liver transplantation are the effective therapy, most patients lost chance due to 
diagnosis at a late stage or underlying liver insufficiency in the setting of cirrhosis [2]. Novel therapies for 
HCC should be developed. A combined therapy is likely to prolong patients’ life and living quality. 
Much attention is attracted to tumor active immunity which purpose is to induce hosts’ immune attack to 
tumor cells. 80% of HCC have a high expressing rate of alpha-fetoprotein (AFP), which could serve as a 
target for immunotherapy [3,4]. AFP is an oncofetal protein during HCC development which could 
generate weaker and less reproducible antitumor protection. How to enhance its immunity is an interesting 
issue. A recombinant vaccine approach may be a good method [5,6]. A number of groups have shown that 
superior levels of T-cell immunity could be generated using a heterogeneous prime-boost strategy, in 
which animals are primed and boosted with a palsmid vector encoding the stimulating molecule and 
targeted peptides [4-6]. In many of these vaccine models [7,8], heat shock protein 70 combined with 
certain antigen prime enhanced immunogenicity, presumably through processing and presenting the 
antigen to host antigen presenting cells (APCs). In the present study, we investigated whether the 
immunogenecity of AFP could be improved by presenting to APCs through HSP70 molecules. We 
constructed a recombinant vaccine containing the molecule chaperon-HSP70 and AFP protein. Then 
primimg mice with the recombinant vaccine, we elicited robust strong protective immunity. 
Materials and methods 
AFP, HSP70 and conjugation 
Mouse AFP was purchased from the GenWay Biotech, Inc. (San Diego, CA). Lyophilized material was 
resuspended in sterile distilled water at 10 mg/ml, aliquoted, and stored at 70°C until use. 
Myco.tuberculosis DnaK-type 70-kD hsp (hsp70) was expressed from a recombinant Escherichia coli 
K12 strain harbouring plasmid pUC119, and purified as described [9]. Recombinant Myco.tuberculosis 
DnaK-type 70-kD hsp (hsp70) was obtained and purified by ATP-agarose chromatography according to 
Peng [10]. 
One milligram each of AFP was coupled to 1 mg of HSP70 in the presence of 0.02% glutaraldehyde 
for 2 h, and then dialysed against PBS overnight. Aliquots of each conjugate were stored at -70°C until use. 
Mice and cell line  
Balb/c mice were provided by Department of Experimental Animal Center at Xian Jiaotong University. 
The investigation was approved by the Ethics Committee on animal Study at Shaanxi University of 
Chinese Medicine (2004-4B). mAFP-producing H22 mice hepatocellular carcinoma cells were maintained 
in RPMI 1640 (life Technologies, Inc.) with 10% fetal bovine serum (Hyclone Technologies, Inc.). The 
supernatants were detected by AFP immunoradiation (Institute of Nuclear Sciences, Beijing) following the 
kit’s procedure. 
 
Mice immunized with recombinant mAFP-HSP70 complex 
 Fifty female Balb/c mice were divided into mAFP/HSP70 group, mAFP group, HSP70 group and 
empty group, PBS control group. Every group had 10 mice. Before injection, each group was diluted in 
saline to 100μg/100μl. Various groups were injected into the left anterior intracutaneous (i.c.) of mice. 
Priming and boosting was performed with 10μg mAFP or mAFP/HSP70, whereas HSP70 and PBS were 
used as controls. A 0.3 insulin syringe with a 25-gauge 0.5-inch-long needle was used for the i.c. injections. 
Mice were boosted i.c. with above proteins twice at 2 weeks intervals after the first priming. 
ELISPOT and ELlSA assay  
 The ELISPOT was used to measure the frequency of cells producing the cytokine IFN-  in 
splenocytes harvested from immunized mice. Two weeks after last immunization, splenocytes were 
harvested and restimulated directly in anti-IFN-  monoclonal antibody (PharMingen) coated ELISPOT 
plate wells in vitro with 5μg/ml of AFP containing 10% fetal bovine serum, 10 units/ml of human 
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interleukin-2. The plates were incubated at 37  for 24h. The plates were then washed and incubated with 
a biotin-conjugated secondary antibody and then developed. The color spots, representing cytokine 
producing cells, were counted under a dissecting microscope. To detect the level of anti-AFP antibody in 
mice, we examined the serum of mice tail vein after the last immunization by ELISA using 
alpha-fetoprotein ELISA kits  (Biotinge Biomedicine Co, LTD., Beijing) following the manufacturer’s 
package insert procedure. 
In vivo tumor challenge   
Another fifty female Balb/c mice were grouped and immunized as above. Tumor challenge was 
performed 2 weeks after the last immunization with 1×105 H22 cells in a single cell suspension per animal 
from tumors progressively growing in syngeneic mice. H22 tumor cells for challenge were washed after 
enzymatic digestion and resuspended in 0.2 ml of PBS per animal to be injected s.c. into the left flank, 
while empty and PBS were used as controls. The sizes of tumors were assessed three times a week using 
calipers. Tumor volume was approximated by the following calculation: 4/3  r3 (r = radius). 
Statistical anlysis 
Results were expressed as mean ± SD. The frequencies of IFN- -producing splenic cells were valued 
using 2 test. The Student t test was performed to analyze the significance of differences between final 
tumor volumes of different groups of animals. P<0.05 was considered statistically significant. 
Results 
Prime-boost vaccines generate AFP T-cells responses and anti-AFP antibody in Balb/c mice  
 Immunization of Balb/c mice with recombinant mAFP/HSP70 vaccine elicited much more strong 
T-cells responses than mAFP group, whereas an i.c. vaccination with HSP70 and PBS groups produced a 
small one (108.50 11.70 IFN-  spots/106 cells vs 41.60 10.40 IFN-  spots/106 cells, 7.32 3.14 
IFN-  spots/106 cells, P<0.01). Recombinant mAFP/HSP70 vaccine immunized mice also produced higher 
level of anti-AFP antibody than mAFP group, while HSP70 and PBS groups produced a lower one (156.32
10.42 μg/mL vs 66.52 7.35 μg/mL, 5.73 2.89 μg/mL, P< 0.01) (Table 1). 
TABLE 1  Spots of  IFN- -producing splenic cells and level of anti-AFP antibody in mice 
 
Groups   
mAFP/HS
P70 

























aP<0.01, VS  group c; bP<0.01, VS  group d; cP<0.01, VS  empty group; dP>0.05, VS  empty group 
Boost immunization protects mice from in vivo tumor challenge  
Balb/c mice were sequentially primed and boosted with mAFP/HSP70, mAFP, HSP70 and PBS 
respectively. Then the mice were challenged with H22 cells. Tumor sizes were significantly smaller in 
mAFP/HSP70 immunized mice than in mAFP and HSP70 immunized mice (42.44 7.14 mm3 vs 392.23
12.46 mm3, 838.63 13.84 mm3, P< 0.01). Although mAFP immuninized group produced an obvious 
tumor, it was still significantly bigger than mAFP/HSP70 group (392.23 12.46 mm3 vs 42.44 7.14 
mm3, P< 0.01 ) (Table 2). 
TABLE 2  Comparision of tumor growth in mice injected with H22 hepatocellular carcinoma cells 
 
Groups 
No. of tumor-bearing/No. of mice 
challenge   
10 days after tumor challenge /Size 
of tumor (mm3)   
20 days after tumor challenge /Size 
of tumor (mm3)   
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mAFP/HSP70 1/10 27.34± 6.22 a 42.44±7.14 a 
mAFP 8/10 86.24± 8.71 c 392.23±12.46     
HSP70 10/10 140.24±11.73  838.63±13.84  
Empty 10/10 142.32±12.33 840.52±13.27 
PBS 10/10 141.53±12.24 836.47±13.62 
aP<0.01, VS  group c; bP<0.01, VS  group d; cP<0.01, VS  empty group; dP>0.05, VS  empty group
 
Discussion 
Recent studies on the immunodominant epitopes of AFP have provided a solution to the obstacle of 
HCC immunotherapy. AFP is produced at low serum levels after birth throughout life [1,2]. The majority 
of human HCC overexpress the oncofetal antigen AFP, Mr 69 000 glycoprotein. Despite being exposed to 
high plasma levels of this oncofetal protein during embryonic development, body has a low immunity to it 
[1,2]. Butterfield et al [11,12] recently found that four peptides of human AFP processed and presented in 
the context of HLA-A0201, could be recognized by the human T cell repertoire, and could be used to 
generate AFP-specific CTL in human T cell cultures. It was also found that murine immune system could 
generate T-cell responses to this oncofetal antigen. Therefore, it may be a better target for immunotherapy. 
But AFP immunization alone still results in lower levels of specific response and poorly reproducible 
protective immunity [4-6]. 
How to enhance host’s active immunity to AFP may be an interesting strategy for HCC therapy. 
Previous studies on AFP specific immunothereapy for HCC included AFP plasmid immunization, 
AFP-transduced dendritic cells (DCs) immunization and AFP plasmid prime-AFP adenovirus boost 
immunization [11-14]. AFP plasmid immunization produced detectable but low levels of AFP specific T 
cell responses and poorly reproducible protective immunity [11,12]. Additional enhancement of the T-cell 
stimulatory effect is DCs engineered to express murine AFP demonstrated a powerful ability to generate 
tumor-specific immune responses [13,14]. However, the need for costly cell culture procedures limited 
their wide availability for clinical use, and the unstable culture technique might yield tolerating vaccine 
[13]. AFP plasmid prime-AFP adenovirus boost immunization could engender significant AFP specific 
T-cell responses and protective immunity in mice [14]. But the miscellaneous procedures precluded their 
use. In the present study, we tested a novel strategy to induce antitumor immunity by a recombinant 
vaccine conjugation AFP to HSP70 in mice. We found the vaccine could elicit strong AFP-specific T-cell 
responses and produced a distinctive protective effect on AFP-producing tumor, compared  with other 
immunized groups. We should pointed out that the single vaccine mAFP also produced a definite 
antitumor immunity, but the effect was not sufficient and satisfactory than that of recombinant vaccine 
mAFP/HSP70. It is of interest to note that the recombinant vaccine provoked not only the considerable 
stability of immunoprotective, but also a detectable level of anti-AFP antibody, although humoral 
immunity alone had a minor limited effect on antitumor.  
In the study, we attributed the successful alpha-fetoprotein specific T-cell responses in mice to the 
HSP70 molecule by mediating APCs to efficient uptake and process of AFP. Numerous investigations had 
shown that HSP70 itself had no antigenicity and its immunogenecity has been attributed to the peptides 
chaperoned carried by itself [15,16]. It has been verified that HSP70 was a better molecule chaperon and 
adjuvant which could process and present weak tumor antigen to MHC-I of host APCs, eliciting specific 
T-cell response and CTL reaction [17]. In our previous study, tumor rejection assay demonstrated that 
recombinant DNA vaccine AFP/HSP70 elicited strong specific antitumor immunity against 
AFP-producing H22 cells than AFP DNA vaccine. Results indicated that AFP immunogenicity can be 
improved greatly by HSP70 molecule and vaccination with DNA encoding HSP70 could increase both 
humoral and T-cell proliferation responses to alpha-fetoprotein. We attributed the successful 
alpha-fetoprotein specific T-cell responses in mice to the HSP70 molecule by mediating APCs to efficient 
uptake and process of AFP [9]. Several studies have shown that HSP70-associated peptides could anchor 
antigen on the cell membrane and directly present it to nature killer cells or  T cells as superantigen 
without being dependent on the stimulation of MHC-I molecules [18,19]. In this experiment, tumor 
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rejection assay demonstrated that recombinant vaccine AFP/HSP70 elicited strong specific antitumor 
immunity against AFP-producing H22 cells than AFP vaccine. The results indicated that AFP 
immunogenicity was improved greatly by HSP70 molecule and vaccination with conjugated HSP70 could 
increase both humoral and T-cell proliferation responses to alpha-fetoprotein.   
In summary, the result suggests that sequential immunization with a recombinant vaccine conjugating 
alpha-fetoprotein to heat shock protein 70 could generate effective AFP-specific T cell responses and 
induce definite antitumor effect on AFP-producing tumor, which may be suitable for some clinical testing 
as a vaccine for HCC. 
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